Imagine if identifying a bacterial infection was as fast as a quick blood test instead of waiting days for a lab to grow bacteria in a dish. This technology acts like a high-speed digital scanner that can spot hundreds of different bacteria in just a few hours. It allows doctors to give the right medicine immediately rather than guessing with general antibiotics.
Traditional bacterial culture methods take several days, leading to prolonged hospital stays and the risky use of broad-spectrum antibiotics based on guesswork.
A PCR-based diagnostic platform including a cloud-based software for data analysis and a test capable of identifying hundreds of bacterial species.
If you are a hospital dealing with long patient stays and high costs due to slow diagnostics — this project developed a PCR-based test that delivers results within 5 hours. This allows for targeted antibiotic use and shorter hospital stays.
If you are a diagnostic company dealing with the need for more comprehensive bacterial panels — this project developed a platform that identifies hundreds of bacterial species with 100% accuracy. This can be integrated into a broader diagnostic product line.
If you are a health authority dealing with the rise of antimicrobial resistance (AMR) — this project developed a rapid diagnostic tool that reduces the empirical use of antibiotics. This helps lower the overall rate of AMR across the population.
Based on available project data, the specific price per test is not mentioned, but the objective describes the diagnostic test as being cost-effective.
Yes, the project developed a cloud-based software platform designed to be robust and scalable for processing complex molecular data.
Based on available project data, specific licensing terms are not provided, but the technology is being prepared for FDA and IVDR approval for market entry.
The project runs from 2023-09-01 to 2025-08-31, focusing on clinical validations to prepare for regulatory approval.
The project includes implementation trials in live hospital settings and the optimization of the interface specifically for hospital workflows.
The project is led by a single SME, INBIOME BV from the Netherlands, which holds 100% of the industry ratio. This lean structure suggests a highly focused development path where the company maintains full control over the IP and commercialization strategy, though it relies on external hospital partners for validation rather than a formal consortium of industrial partners.
Contact INBIOME BV in the Netherlands
Contact us to explore licensing opportunities for this rapid diagnostic platform.
